9 results on '"Martine Tebacher-Alt"'
Search Results
2. Acute Renal Failure Related to High Doses of Acyclovir (15 mg/kg/8 h) during Treatment of Varicella Zoster Virus Encephalitis
- Author
-
Martin Martinot, Martine Tebacher-Alt, Samira Fafi-Kremer, Mahsa Mohseni-Zadeh, Monica Groza, Alexandre Klein, and Karine Demesmay
- Subjects
Male ,Herpesvirus 3, Human ,viruses ,Acyclovir ,030312 virology ,medicine.disease_cause ,Antiviral Agents ,03 medical and health sciences ,medicine ,High doses ,Humans ,Pharmacology (medical) ,Aged ,Encephalitis, Varicella Zoster ,Pharmacology ,0303 health sciences ,integumentary system ,business.industry ,Varicella zoster virus ,virus diseases ,Electroencephalography ,Acute Kidney Injury ,Middle Aged ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Magnetic Resonance Imaging ,Virology ,Regimen ,Infectious Diseases ,Herpes simplex virus ,Female ,business ,Biomarkers ,Encephalitis - Abstract
Varicella zoster virus (VZV) is less susceptible than herpes simplex virus to acyclovir. The optimal acyclovir regimen during VZV encephalitis remains unknown. We report two cases of acute renal failure after an increase in acyclovir dosage from 10 mg to 15 mg/kg/8 h during the treatment of VZV encephalitis according to French guidelines.
- Published
- 2018
3. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
- Author
-
Mahsa Mohseni-Zadeh, Martine Tebacher-Alt, Martin Martinot, Camille Martinez, Samira Fafi-Kremer, Dragos M Gorun, Guido Ahle, and Inesa Petrosyan
- Subjects
Male ,0301 basic medicine ,Oncology ,Hydrocortisone ,Epidemiology ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,JC virus ,immune checkpoint inhibitor ,lcsh:Medicine ,medicine.disease_cause ,progressive multifocal leukoencephalopathy ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,030212 general & internal medicine ,Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab ,medicine.diagnostic_test ,Progressive multifocal leukoencephalopathy ,Leukoencephalopathy, Progressive Multifocal ,Middle Aged ,Hodgkin Disease ,Magnetic Resonance Imaging ,meningtitis/encephalaitis ,Infectious Diseases ,Female ,Nivolumab ,Microbiology (medical) ,medicine.medical_specialty ,Viremia ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,meningtitis/encephalitis ,Internal medicine ,Pharmacovigilance ,Research Letter ,medicine ,Humans ,viruses ,lcsh:RC109-216 ,HIV/AIDS and other retroviruses ,Aged ,nivolumab ,business.industry ,lcsh:R ,Cancer ,Magnetic resonance imaging ,Immunotherapy ,medicine.disease ,030104 developmental biology ,business - Abstract
Progressive multifocal leukoencephalopathy (PML) is increasingly being reported in patients undergoing immunotherapy. We report a case of progressive multifocal leukoencephalopathy after treatment with nivolumab, a PD-1 blocker that is used to restore impaired T-cell responses in patients with cancer and infections. Data for 4 other cases were obtained from pharmacovigilance databases.
- Published
- 2018
4. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database
- Author
-
Laurent Arnaud, Thierry Martin, Philippe Mertz, Aude Lambert, François Chasset, Martine Tebacher-Alt, Joe-Elie Salem, Jean Sibilia, P.E. Gavand, Charlotte Muller, Bénédicte Lebrun-Vignes, CHU Strasbourg, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Strasbourg (UNISTRA), Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Régional de Pharmacovigilance (CRPV), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Sorbonne Université (SU), Service de pharmacologie médicale [CHU Pitié-Salpêtrière], and CHU Pitié-Salpêtrière [AP-HP]
- Subjects
Male ,0301 basic medicine ,Databases, Factual ,[SDV]Life Sciences [q-bio] ,computer.software_genre ,Etanercept ,0302 clinical medicine ,systemic lupus erythematosus ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,skin and connective tissue diseases ,media_common ,Systemic lupus erythematosus ,Database ,Middle Aged ,Hydralazine ,3. Good health ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Antirheumatic Agents ,Female ,medicine.drug ,Adult ,Drug ,media_common.quotation_subject ,Immunology ,Procainamide ,World Health Organization ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Rheumatology ,Pharmacovigilance ,medicine ,Adalimumab ,Humans ,Adverse effect ,Retrospective Studies ,030203 arthritis & rheumatology ,business.industry ,drug-induced lupus ,medicine.disease ,Infliximab ,030104 developmental biology ,adverse-drug reaction ,pharmacovigilance ,business ,computer ,Adverse drug reaction - Abstract
ObjectiveDrug-induced lupus (DIL) is an idiosyncratic side effect of treatments in which symptoms overlap with those of systemic lupus erythematosus (SLE). The spectrum of DIL constantly evolves with that of the pharmacopoeia. Here, we used VigiBase, the WHO global individual case safety reports (ICSRs) database, to identify the main drugs associated with DIL.MethodsWe analysed all ICSRs classified as ‘systemic lupus erythematosus’ according to the Medical Dictionary for Drug Regulatory Activities term (preferred term level) in VigiBase. The drugs considered in the analysis were those not used to treat SLE, with a positive lower end of the 95% credibility interval for the information component (IC025) ≥0, an indicator value for disproportionate Bayesian reporting.ResultsA total of 12 166 DIL ICSRs were identified using VigiBase. From those, 8163 ICSRs reporting on 118 suspected drugs with IC025 ≥0 were extracted. The median age at DIL onset was 49 years and the female to male sex ratio was 4.3. The median delay between start of suspected treatment and DIL occurrence was 172 days. DIL was reported as serious adverse event in 55.4%. Among the 118 suspected drugs, 42 had not been previously reported in association with DIL. The drugs associated with the highest number of DIL cases were infliximab, adalimumab, etanercept, procainamide and hydralazine.ConclusionThis study enables the identification of 118 drugs associated with DIL. The list of suspected drugs may prove useful to physicians when confronted with potential DIL cases.Trial registration numberNCT03480529.
- Published
- 2019
5. Aplasie cutanée congénitale et antithyroïdiens de synthèse au cours de la grossesse : série de cas et revue de la littérature
- Author
-
C. Sachs, Bernard Cribier, Dan Lipsker, Martine Tebacher-Alt, and M. Mark
- Subjects
0301 basic medicine ,Gynecology ,medicine.medical_specialty ,Antithyroid drugs ,business.industry ,030209 endocrinology & metabolism ,Dermatology ,030105 genetics & heredity ,03 medical and health sciences ,Methimazole ,0302 clinical medicine ,Prenatal Exposure Delayed Effects ,medicine ,business ,medicine.drug - Abstract
Resume Introduction L’aplasie cutanee congenitale (ACC) apres exposition in utero aux antithyroidiens de synthese (ATS) de type methimazole/carbimazole (MTZ/CBZ) est decrite depuis 1972. Elle s’integre actuellement dans le concept d’embryopathie au MTZ/CMZ, mais reste mal caracterisee et discutee. A l’occasion de deux cas observes dans un court laps de temps, nous avons effectue une revue de la litterature et interroge la base de donnees nationale de pharmacovigilance. Materiel et methodes Une recherche d’articles scientifiques a ete realisee en interrogeant la base de donnees informatique Medline avec les mots cles « aplasia cutis congenita », « birth skin defects », « pregnancy » et « drug » ; tous les articles rapportant des cas d’ACC sous ATS ont ete inclus. A partir de la base de donnees nationale de pharmacovigilance, tous les cas declares d’ACC sous ATS ont ete inclus. Resultats Trois cent soixante-huit articles etaient references ; 27 ont ete retenus plus 4 additionnels, mentionnes dans les differentes publications, conduisant a 59 cas d’ACC sous MTZ/CMZ rapportes dans la litterature, avec une imputabilite intrinseque jugee plausible ou douteuse. L’ACC etait generalement isolee, unique et de petite taille, localisee au cuir chevelu median. L’exposition avait eu lieu durant les premieres semaines d’amenorrhee. On comptait six cas familiaux chez des freres et sœurs. Dix cas ont ete notifies a la pharmacovigilance dans toute la France. Discussion L’ACC sous MTZ/CMZ, isolee ou non, est une entite a connaitre. Il s’agit vraisemblablement d’un effet teratogene propre de ces medicaments, favorise par une susceptibilite genetique.
- Published
- 2016
6. Acute generalized exanthematous pustulosis caused by an iodinated contrast radiocontrast medium for computed tomography arthrography of the knee
- Author
-
Catherine Schissler, Chloé Moulinas, Jean-Marie Siedel, Martine Tebacher-Alt, C. Velter, Bernard Cribier, Dan Lipsker, and VELTER, Charles
- Subjects
medicine.medical_specialty ,Knee Joint ,Contrast Media ,Computed tomography ,Dermatology ,Iodine Radioisotopes ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Iodinated contrast ,Humans ,Immunology and Allergy ,Medicine ,Arthrography ,ComputingMilieux_MISCELLANEOUS ,medicine.diagnostic_test ,business.industry ,Middle Aged ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,Acute generalized exanthematous pustulosis ,medicine.disease ,Iodixanol ,Tomography x ray computed ,Acute Generalized Exanthematous Pustulosis ,030228 respiratory system ,Female ,Radiology ,Tomography, X-Ray Computed ,business ,medicine.drug - Published
- 2017
7. Eruptive nevi under tocilizumab: first case report and data analysis
- Author
-
J.L. Pasquali, Dan Lipsker, Martine Tebacher-Alt, Y. Mansour, and A. Lambert
- Subjects
030203 arthritis & rheumatology ,medicine.medical_specialty ,business.industry ,MEDLINE ,Dermatology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Infectious Diseases ,Tocilizumab ,chemistry ,Monoclonal ,Medicine ,business - Published
- 2018
8. Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review
- Author
-
Martine Tebacher-Alt, Elisabeth Quoix, Anthony Gschwend, Florence Gass-Jégu, Anne-Cécile Gairard-Dory, Bénédicte Gourieux, and Bertrand Mennecier
- Subjects
Pulmonary and Respiratory Medicine ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Stomach Diseases ,Antineoplastic Agents ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,Erlotinib Hydrochloride ,0302 clinical medicine ,Fatal Outcome ,Gastrointestinal perforation ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,heterocyclic compounds ,In patient ,Epidermal growth factor receptor ,neoplasms ,Protein Kinase Inhibitors ,Chemotherapy ,biology ,business.industry ,Middle Aged ,medicine.disease ,respiratory tract diseases ,Surgery ,Ciprofloxacin ,Oncology ,Intestinal Perforation ,030220 oncology & carcinogenesis ,Concomitant ,biology.protein ,Radiography, Thoracic ,Erlotinib ,business ,Tomography, X-Ray Computed ,hormones, hormone substitutes, and hormone antagonists ,Adverse drug reaction ,medicine.drug - Abstract
Erlotinib has been approved as second-line treatment in patients with non-small cell lung cancer (NSCLC) experiencing relapse after first-line platinum-based chemotherapy. Herein, we report two occurrences of erlotinib-associated gastrointestinal perforation (GIP) in NSCLC patients. Two patients aged 60 and 79 years received erlotinib as third- and second-line NSCLC treatment, respectively. GIP occurred following 3 weeks and 6 months of erlotinib treatment, leading to death a few days later in both patients, neither of whom had any intestinal metastasis. Risk factors related to erlotinib-induced GIP were concomitant oral corticosteroid therapy and ciprofloxacin administration, which may result in erlotinib overexposure. GIP is a severe adverse drug reaction of erlotinib, infrequently described in the literature, compared to other targeted therapies. The lethal risk of erlotinib-associated GIP should be taken into account when evaluating the benefit-risk balance of erlotinib in patients without epidermal growth factor receptor activating mutations.
- Published
- 2016
9. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment
- Author
-
Virginie Bres, Jean-Louis Montastruc, Sylvie Favrelière, Maryse Lapeyre-Mestre, Cédric Mauprivez, Aurélie Grandvuillemin, Johana Béné, G. Moulis, Martine Tebacher-Alt, Nadine Petitpain, Laure Villeval-Federici, Claire Guy, Emmanuelle Weber, Marie-Laure Laroche, Haleh Bagheri, Annie-Pierre Jonville-Béra, Laurent Sailler, Bernadette Baldin, Gwenaëlle Veyrac, Service de Néphrologie - Médecine Interne, CHU Amiens-Picardie-hôpital Sud, Service de pharmacologie, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Hôpital Nord [Saint-Étienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Pharmacologie Clinique et Toxicologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de rhumatologie, CHU Purpan, Handicap, Activité, Vieillissement, Autonomie, Environnement (HAVAE), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Unité Pédagogique et de Recherche de Biologie et Physiologie Animale, Université Jean Lorougnon Guédé (UJloG ), Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de pharmacologie médicale et clinique, CHU Toulouse [Toulouse], Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS)-Université d'Auvergne - Clermont-Ferrand I (UdA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre de Rhumatologie [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Male ,medicine.medical_specialty ,Recombinant Fusion Proteins ,Eltrombopag ,Receptors, Fc ,030204 cardiovascular system & hematology ,Benzoates ,Pharmacovigilance ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Risk factor ,ComputingMilieux_MISCELLANEOUS ,Aged ,Romiplostim ,business.industry ,Absolute risk reduction ,Odds ratio ,Middle Aged ,medicine.disease ,3. Good health ,Surgery ,Gastrointestinal Tract ,Hydrazines ,Thrombopoietin ,chemistry ,030220 oncology & carcinogenesis ,Pharmacodynamics ,Pyrazoles ,Female ,France ,business ,Receptors, Thrombopoietin ,Adverse drug reaction ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,medicine.drug - Abstract
Background Romiplostim and eltrombopag, the two marketed thrombopoietin receptor agonists (TPO-RAs), have distinct binding sites and might have distinct pharmacodynamic mechanisms. The aim of this study was to compare their adverse drug reaction (ADR) patterns. Methods We selected in the French PharmacoVigilance Database all ADRs associated with TPO-RAs from TPO-RA marketing until the 31st of December 2013. Medical charts were reviewed. We conducted disproportionality analyses comparing romiplostim exposure in the reports of a given ADR pattern (thrombosis, neurological, cutaneous, gastrointestinal or hematological) to romiplostim exposure in all other TPO-RA-related ADR reports. Reporting Odds Ratios (RORs) were adjusted for age and gender. We also compared the number of reports of a given ADR pattern per million daily defined doses (DDDs) dispensed in France during the study period. Results We described 45 reports (53 ADRs) with romiplostim and 26 reports (37 ADRs) with eltrombopag. There were 19 venous thromboses. At least one other risk factor was present in 83.3% of the cases. Ten (55.6%) patients had been splenectomized previously. There were eight arterial thromboses. Another risk factor was noticed in all cases. There was no signal for an excess risk of thrombosis with romiplostim versus eltrombopag (ROR: 1.45, 95% CI [0.48–4.45]). There was a signal for a higher risk of gastrointestinal ADRs with eltrombopag (ROR: 30.28, 95% CI [3.23–383.86]) and of hematological ADRs with romiplostim (ROR: 14.36, 95% CI [1.73–119.08]). Dispensing data-adjusted comparisons led to similar results. Conclusions This study suggests different ADR patterns between romiplostim and eltrombopag.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.